Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioChaperone PDGF-BB vs Becaplermin in Diabetic Foot Ulcer
NCT01098357Phase 2Completed
- Sponsor
- Virchow Group
- Start
- Jun 2010
- Primary completion
- Feb 2011
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of becaplermin in diabetic foot ulcer (DFU) (4 arms), sponsored by Virchow Group. Primary endpoint: Incidence of complete wound closure at 20 weeks. Started Jun 2010; status: completed.
02
Drugs
becaplermin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT01098357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01098357.